FIELD: biotechnology.
SUBSTANCE: antibody conjugate for targeted interaction with CD19, as well as to a pharmaceutical composition containing it.
EFFECT: treating a disease associated with pathological expression of CD19.
63 cl, 6 dwg, 2 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
NEW ANTI-CD19 ANTIBODIES | 2018 |
|
RU2791445C2 |
ANTIBODY AND DRUG CONJUGATES FOR DESTRUCTION OF HEMATOPOIETIC STEM CELLS | 2017 |
|
RU2781444C2 |
ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR AND APPLICATION THEREOF | 2019 |
|
RU2778023C1 |
ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
Authors
Dates
2023-10-31—Published
2019-05-09—Filed